This randomized clinical trial compares 100-mg versus 300-mg maintenance doses of extended-release buprenorphine. While overall efficacy was similar, the 300-mg dose significantly improved abstinence rates among heavy fentanyl users, offering a potential pathway for personalized treatment in high-risk populations.